Innovative companies in the pharma/biotech field face generic competition earlier than ever before. It is vital for companies to have a cohesive IP strategy as a drug progresses through clinical trial milestones to develop strategic claiming strategies and maximize patent term. Once a drug reaches Phase II or Phase III clinical trials, it is often advantageous for companies to conduct a “health check” on their IP portfolios, critically analyzing issued patents and pending applications for potential weaknesses and addressing them well before a New Drug Application (NDA) submission and product launch.
In this webinar, the panel will discuss several examples of issues that can arise during an IP portfolio “health check,” including:
Recorded: View On-Demand
Speakers:
Michele Bosch
Pier DeRoo
Moderator:
Charles Collins-Chase
Date:
Wednesday, September 24, 2019
Time:
10:00 - 11:00 a.m. PDT
1:00 - 2:00 p.m. EDT
19:00 - 20:00 p.m. CEST
Scheduling Conflict? Finnegan records all hosted webinars. To view the recorded program, simply register for the webinar and you will receive an access link shortly after the live program is complete.
claim construction, new drug application (NDA), Obviousness-type Double Patenting (OTDP), Orange Book, 2019 Top Insights
June 10-12, 2024
San Francisco
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.